- cafead   Oct 22, 2023 at 06:12: PM
via Bladder cancer hasn’t been the easiest tumor type to tackle for immunotherapies. Bristol Myers Squibb has found success here with its Opdivo, but the win was overshadowed by competitor data.
article source
article source